Exploring the Nature of the Enzyme Glycogen Synthase Kinase 3 (GSK-3) Providing a Thorough Introduction and Discussion.DUBLIN, Ireland -- Research and Markets (http://www.researchandmarkets.com/reports/c45349) has announced the addition of Glycogen Synthase synthase /syn·thase/ (-thas) a term used in the names of some enzymes, particularly lyases, when the synthetic aspect of the reaction is dominant or emphasized. syn·thase n. Kinase 3 (GSK-3) and Its Inhibitors: Drug Discovery and Development to their offering. The new potential of an "old" enzyme Glycogen Synthase glycogen synthase n. An enzyme that catalyzes the transfer of glucose from UDP-glucose to glycogen. Kinase 3 (GSK-3) was discovered about twenty-five years ago but had garnered little interest until recently. Now many researchers believe that there is much potential for this "old" enzyme and are re-examining its biological characteristics. GSK-3 and its inhibitors could lead to effective treatments for neurogenerative disorders, type II diabetes Type II diabetes Type II diabetes is the most common form of diabetes and usually appears in middle aged adults. It is often associated with obesity and may be delayed or controlled with diet and exercise. Mentioned in: Diabetic Ketoacidosis , depression and bipolar disorder bipolar disorder, formerly manic-depressive disorder or manic-depression, severe mental disorder involving manic episodes that are usually accompanied by episodes of depression. , and some forms of cancer. This book explores the nature of this promising enzyme, providing a thorough introduction and discussion, and mentions the birth of several chemical families of GSK-3 inhibitors with varying selectivity. Specific topics relating to GSK-3 covered in this book include: * Cellular functions * Neuronal cell biology * Crystal structures * Kinase-kinase and site-site interactions in the phosphorylation phosphorylation, chemical process in which a phosphate group is added to an organic molecule. In living cells phosphorylation is associated with respiration, which takes place in the cell's mitochondria, and photosynthesis, which takes place in the chloroplasts. of tau * Therapeutic target in human pathology * Role in stem cells stem cells, unspecialized human or animal cells that can produce mature specialized body cells and at the same time replicate themselves. Embryonic stem cells are derived from a blastocyst (the blastula typical of placental mammals; see embryo), which is very young * Physiology studies * Development and therapeutic potential of GSK-3 inhibitors Gathering and systematically analyzing relevant and up-to-date information about GSK-3 and its known inhibitors, this book will aid researchers interested in drug design and development, especially those directly involved in the fascinating world of GSK-3. Author Information ANA MARTINEZ is the Research and Development Director for NeuroPharma. She has been and still is an active researcher in the design and synthesis of GSK-3 inhibitors. ANA CASTRO is the Medicinal Chemistry Director of NeuroPharma. She was formerly a tenured ten·ured adj. Having tenure: tenured civil servants; tenured faculty. Adj. 1. tenured scientist at the Medicinal Chemistry Institute. MIGUEL MEDINA is the Drug Discovery Director at NeuroPharma. He was formerly an instructor at the Brigham and Womens Hospital and the Harvard Medical School Harvard Medical School (HMS) is one of the graduate schools of Harvard University. It is a prestigious American medical school located in the Longwood Medical Area of the Mission Hill neighborhood of Boston, Massachusetts. . Content Outline: Foreword: The Origins of GSK-3. Preface. Acknowledgments. Contributors. Abbreviations. PART I: CELLULAR FUNCTIONS OF GSK-3. 1. Glycogen Synthase Kinase-3 an Introductory Synopsis . 2. Glycogen-Synthase-Kinase-E (GSK-3E) a Key Signaling Enzyme: A Developmental Neurobiological neu·ro·bi·ol·o·gy n. The biological study of the nervous system or any part of it. neu  ro·bi Perspective. 3. Role of GSK GSK GlaxoSmithKline plc (pharmaceutical company) GSK Glycogen Synthase Kinase GSK Gruppentraining Sozialer Kompetenzen (Germany) GSK Greenland Shark (FAO fish species code) 3/Shaggy in neuronal cell biology. 4. The Crystal Structures of Glycogen Synthase Kinase 3. 5. Kinase-Kinase and Site-Site Interactions in the Phosphorylation of Tau by GSK-3. PART II: GSK3 AS A THERAPEUTIC TARGET IN HUMAN PATHOLOGY. 6. GSK-3, a Key Player in Alzheimer's disease. 7. Glycogen Synthase Kinase-3: A Target for Novel Mood Disorder Treatments. 8. GSK3 and Stem Cells. 9. Glycogen Synthase Kinase-3: role in Neurodegeneration and Neuroprotection. 10. Protein Kinase Inhibitors. Assay Development. 11. Animal Models with Modified Expression of GSK-3 for the Study of Its Physiology and of Its Implications in Human Pathologies. PART III: GSK-3 INHIBITORS: DEVELOPMENT AND THERAPEUTIC POTENTIAL. 12. Lithium, the Seminal GSK3 Inhibitor. 13. Inhibition of GSK3 as Therapeutic Strategy in Disease: Efficacy of AR-A014418. 14. TDZD's: Selective and ATP ATP: see adenosine triphosphate. ATP in full adenosine triphosphate Organic compound, substrate in many enzyme-catalyzed reactions (see catalysis) in the cells of animals, plants, and microorganisms. Non Competitive Glycogen Synthase Kinase-3 Inhibitors. 15. 3-Amino Pyrazoles as Potent and Selective Glycogen Synthase (GSK-3) Inhibitors. 16. Marine compounds as a new source for Glycogen Synthase Kinase-3 Inhibitors. Index. For more information visit http://www.researchandmarkets.com/reports/c45349 |
|
||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion